Richard B. Kim, MD, FRCPC, Division Chair
Dr. Kim received his medical degree from University of Saskatchewan, Canada in 1987. After completing an internship and residency training at Royal University hospital in Saskatoon Canada in 1991, he went on to carry out postdoctoral fellowship training in Clinical Pharmacology at Vanderbilt University.
In 1994, upon completion of his fellowship training, he remained at Vanderbilt Clinical Pharmacology as a faculty member until 2006. He is currently Professor and Chair of the Division of Clinical Pharmacology in the Department of Medicine at the University of Western Ontario in London, Canada. His research interest is that of understanding the molecular basis of interindividual differences in drug disposition and the application of such finding to the emerging field of Personalized Medicine.
Research areas under active investigation in his laboratory include that of drug transporters, CYP enzymes, and the pathways involved in the regulated expression of such proteins. He is a member of ASCPT, ISSX, and AAPS. He is an editor for the Medical Letter Handbook of Adverse Drug Interactions, and an associate editor for Molecular Pharmacology. He is a fellow of AAPS, and member of the American Society for Clinical Investigation (ASCI).

Publications
2000  2001  2002  2003  2004
<<<        >>>

Abu-Zahra T.N., Wolkoff A.W., Kim R.B., and Pang K.S.: Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Met. Disp., 28:801-806, 2000. [Pubmed]

Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J.J., Wilkinson G.R., and Kim R.B.: Pharmacologic inhibition of P-glycoprotein enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Met. Disp., 28:655-660, 2000. [Pubmed]

Jisaka M., Kim R.B., Boeglin W.E., Brash A.R.: Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2. J. Biol. Chem., 275:1287-1293, 2000. [Pubmed]

Kim R.B.: Drug efflux transporters and antiviral drug therapy. Emerging Therapeutic Targets, 4:439-446, 2000. [Pubmed]

Kim R.B.: Transporters and drug disposition. Curr. Opin. Drug Discovery. Dev., 3:94-101, 2000. [Pubmed]

Lecureur V., Sun D., Hargrove P., Schuetz E.G., Kim R.B., Lan L-B., and Schuetz J.D.: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol. Pharmacol., 57:24-35, 2000. [Pubmed]

Wandel C., Kim R.B., Guengerich F.P., and Wood A.J.J.: Mibefradil is a substrate of P-glycoprotein, and a potent inhibitor of both P-glycoprotein and CYP3A. Drug. Met. Disp., 28:873-879, 2000. [Pubmed]

Xie H.G., Stein C.M., Kim R.B., Sofowora G., Dishy V., Gainer J.V., Brown N.J., Haines J.L., and Wood A.J.J.: Human beta-2 adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans. Clin. Pharmacol. Ther, 67:670-675, 2000. [Pubmed]